Company: RGNT
Filing Date: 2025-01-24
Form Type: DRS
Source: 0001213900-25-006245
Chunk: 177

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-24
Form: DRS
Chunk 177
---
 Majority and the terms thereof may not be inconsistent
with the company’s stated compensation policy.

Pursuant to regulations promulgated
under the Companies Law, certain transactions and arrangements with a controlling shareholder or his or her relative, or with directors
or office holders, which would otherwise require approval of a company’s shareholders, may be exempt from shareholder approval under
certain conditions.

The Companies Law requires
that every shareholder that participates, in person, by proxy or by voting instrument, in a vote regarding a transaction with a controlling
shareholder, must indicate in advance or in the ballot whether or not that shareholder has a personal interest in the vote in question.
Failure to so indicate will result in the invalidation of that shareholder’s vote. However, according to the Companies Law Regulations
(exemptions for companies whose securities are listed for trading on a stock exchange outside of Israel) 5760-2000 that apply to the Company,
by signing and submitting a proxy card, a shareholder declares and approves that he has no personal interest in the approval of any of
the items on a general meeting agenda that requires such declaration under the Companies Law, with the exception of a personal interest
that the shareholder positively informed the company about.

Disclosure of Compensation of Executive Officers

For so long as we qualify
as a foreign private issuer, we are not required to comply with the proxy rules applicable to U.S. domestic companies, including the requirement
applicable to emerging growth companies to disclose the compensation of our chief executive officer and other two most highly compensated
executive officers on an individual, rather than an aggregate, basis. Nevertheless, regulations promulgated under the Companies Law will
require us, after we become a public company, to disclose the annual compensation of our five most highly compensated office holders on
an individual basis, rather than on an aggregate basis. This disclosure will not be as extensive as that required of a U.S. domestic issuer.
We intend to commence providing such disclosure, at the latest, in the proxy statement for our first annual general meeting of shareholders
following this offering, which will be furnished under cover of a Form 6-K and we may elect to provide such information at an earlier
date.

Compensation of Directors and Executive Officers

Directors. Under the
Companies Law, the compensation of our directors requires the approval of our compensation committee, the subsequent approval of the board
of directors and, unless exempted under regulations promulgated under the Companies Law, the approval of the shareholders at a general
meeting